Возраст домена | 27 лет |
Дата окончания | Истек срок регистрации |
PR | 4 |
ИКС | n/a |
Страниц в Google | 3 |
Страниц в Яндексе | 7 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | Нет данных |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
RxAbbVie
n/a
n/a
UTF-8
34.37 КБ
1 003
8 518 симв.
7 409 симв.
Ссылок в Alexa | 114 |
Данные linkpad ( 18 Ноября 2011 ) | |
Количество ссылок на сайт | 149 |
Количество доменов, которые ссылаются на сайт | 52 |
Количество найденных анкоров | 50 |
Исходящие (внешние) ссылки домена | 0 |
Количество доменов, на которые ссылается сайт | 0 |
Количество исходящих анкоров | 0 |
Внешние ссылки главной страницы ( 6 ) | |
fda.gov/medwatch/ | www.fda.gov/medwatch |
pparx.org/ | www.pparx.org |
abbviemedinfo.com/ | www.abbviemedinfo.com |
abbvie.com/contactus.html | Contact Us |
abbvie.com/privacy.html | Privacy policy |
abbvie.com/termsofuse.html | Terms of use |
Внутренние ссылки главной страницы ( 102 ) | |
<img> | |
/pdf/androgel_PI.pdf | AndroGel® (testosterone gel) 1% Full Prescribing Information |
/pdf/androgel_medguide.pdf | AndroGel® (testosterone gel) 1% Medication Guide |
/pdf/androgel1_62_PI.pdf | AndroGel® (testosterone gel) 1.62% Full Prescribing Information |
/pdf/androgel1_62_medguide.pdf | AndroGel® (testosterone gel) 1.62% Medication Guide |
/pdf/creon_PI.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information |
/pdf/creon_pi_CHI.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Chinese |
/pdf/creon_pi_KOR.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Korean |
/pdf/creon_pi_RUS.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Russian |
/pdf/creon_pi_SPA.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Spanish |
/pdf/creon_medguide.pdf | CREON® (pancrelipase) Delayed-Release Capsules Medication Guide |
/pdf/depacon.pdf | Depacon® (valproate sodium injection) |
/pdf/depakene.pdf | DEPAKENE® (valproic acid capsules and oral solution, USP) |
/pdf/depakene_medguide.pdf | DEPAKENE® (valproic acid capsules and oral solution, USP) Medication Guide |
/pdf/depakote.pdf | Depakote® (divalproex sodium) Delayed-Release Tablets |
/pdf/depakote_medguide.pdf | Depakote® (divalproex sodium) Delayed-Release Tablets Medication Guide |
/pdf/dep3.pdf | Depakote® ER (divalproex sodium) Extended-Release Tablets |
/pdf/dep3_medguide.pdf | Depakote® ER (divalproex sodium) Extended-Release Tablets Medication Guide |
/pdf/dep2.pdf | Depakote® Sprinkle Capsules (divalproex sodium delayed-release capsules) |
/pdf/dep2_medguide.pdf | Depakote® Sprinkle Capsules (divalproex sodium delayed-release capsules) Medication Guide |
/pdf/duopa_pi.pdf | DUOPA (carbidopa and levodopa) enteral suspension Full Prescribing Information with Medication Guide and Patient Instructions Fo... |
/pdf/duopa_SPA.pdf | DUOPA (carbidopa and levodopa) enteral suspension Full Prescribing Information with Medication Guide and Patient Instructions Fo... |
/pdf/duopa_pump_manual.pdf | DUOPA (carbidopa and levodopa) enteral suspension CADD-Legacy® 1400 Pump Operator’s Manual |
/pdf/duopa_ifu_cpack.pdf.pdf | DUOPA: AbbVie Chest Pack Instructions For Use |
/pdf/duopa_ifu_cbpack.pdf.pdf | DUOPA: AbbVie Cross Body Pack Instructions For Use |
/pdf/duopa_ifu_hpack.pdf.pdf | DUOPA: AbbVie Hip Pack Instructions For Use |
/pdf/abbvie_instr_jtube_mrisupp.pdf | DUOPA: AbbVie J Tube Instructions For Use, Including MRI Safety Information Supplement |
/pdf/duopa_ifu_lvest.pdf.pdf | DUOPA: AbbVie Lightweight Vest Instructions For Use |
/pdf/abbvie_mrisupp.pdf | DUOPA: AbbVie MRI Safety Information Supplement |
/pdf/abbvie_instr_njtube.pdf | DUOPA: AbbVie NJ Tube Instructions For Use |
/pdf/abbvie_instr_pegtube.pdf | DUOPA: AbbVie PEG Tube Kit Instructions For Use |
/pdf/duopa_ifu_svest.pdf.pdf | DUOPA: AbbVie Snug Vest Instructions For Use |
/pdf/gengraf-cap.pdf | GENGRAF® Capsules (cyclosporine capsules, USP) |
/pdf/gengraf-oral.pdf | Gengraf® Oral Solution (cyclosporine oral solution, USP) |
/pdf/humira.pdf | HUMIRA® (adalimumab) Full Prescribing Information |
/htm/humira/humira_pi.html | HUMIRA® (adalimumab) Full Prescribing Information |
/pdf/humira_CHI.pdf | HUMIRA® (adalimumab) Full Prescribing Information - Chinese |
/pdf/humira_SPA.pdf | HUMIRA® (adalimumab) Full Prescribing Information - Spanish |
/pdf/humira_medguide.pdf | HUMIRA® (adalimumab) Medication Guide |
/pdf/ktab.pdf | K-TAB® (potassium chloride extended-release tablets, USP) |
/pdf/kaletracap_PI.pdf | KALETRA® (lopinavir/ritonavir) Capsules - Full Prescribing Information |
/pdf/kaletratabpi.pdf | KALETRA® (lopinavir/ritonavir) Tablets and KALETRA® (lopinavir/ritonavir) Oral Solution - Full Prescribing Information |
/pdf/kaletratab_medguide.pdf | KALETRA® (lopinavir/ritonavir) Tablets and KALETRA® (lopinavir/ritonavir) Oral Solution - Medication Guide |
/pdf/lupaneta_3_75_pi.pdf | LUPANETA PACK® (leuprolide acetate for depot suspension and norethindrone acetate tablets) 3.75 mg |
/pdf/lupaneta_11_25_pi.pdf | LUPANETA PACK® (leuprolide acetate for depot suspension and norethindrone acetate tablets) 11.25 mg |
/pdf/lupron3month11_25mg.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3 Month 11.25 mg |
/pdf/luprongyne_SPA.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3.75 mg and 3 Month 11.25 mg - Spanish |
/pdf/lupron3_75mg.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3.75 mg and 3 Month 11.25 mg |
/pdf/lupronuro_pi.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) URO |
/pdf/lupronpediatric.pdf | LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) |
/pdf/lupronpediatric_SPA.pdf | LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) - Spanish |
/pdf/marinol_PI.pdf | MARINOL® (dronabinol) Capsules Full Prescribing Information |
/pdf/marinol_PIL.pdf | MARINOL® (dronabinol) Capsules Patient Information |
/pdf/mavyret_pi.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Full Prescribing Information |
/pdf/mavyret_SPA.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Full Prescribing Information - Spanish |
/pdf/mavyret_PIL.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Patient Information |
/pdf/mavyret_PIL_SPA.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Patient Information - Spanish |
/pdf/mivacron_PI.pdf | MIVACRON® Injection (mivacurium chloride) Full Prescribing Information |
/pdf/moderiba_PI.pdf | Moderiba™ (ribavirin, USP) Tablets |
/htm/moderiba/moderiba_pi.html | Moderiba™ (ribavirin, USP) Tablets |
/pdf/niaspan.pdf | NIASPAN® (niacin extended-release tablets) [film-coated] |
/pdf/Nimbex.pdf | NIMBEX® (cisatracurium besylate) |
/pdf/nimbex_novaplus_pi.pdf | NIMBEX® (cisatracurium besylate) Injection NOVAPLUS® Full Prescribing Information |
/pdf/nimbex_pi.pdf | NIMBEX® (cisatracurium besylate) Injection PremierProRx® Full Prescribing Information |
/pdf/norpi2a.pdf | NORVIR® Capsules (ritonavir capsules) |
/pdf/norvirtab_pi.pdf | NORVIR® (ritonavir tablets, oral solution, and oral powder) |
/pdf/orilissa_pi.pdf | ORILISSA® (elagolix) tablets, for oral use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide |
/pdf/orilissa_pi_SPA.pdf | ORILISSA® (elagolix) tablets, for oral use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide - Spanish |
/pdf/orilissa_medguide.pdf | ORILISSA® (elagolix) tablets, for oral use, 150 mg and 200 mg, Medication Guide |
/pdf/rinvoq_pi.pdf | RINVOQ™ (upadacitinib) extended-release tablets, for oral use Full Prescribing Information |
/pdf/rinvoq_pi_SPA.pdf | RINVOQ™ (upadacitinib) extended-release tablets, for oral use Full Prescribing Information - Spanish |
/pdf/rinvoq_medguide.pdf | RINVOQ™ (upadacitinib) extended-release tablets, for oral use Medication Guide |
/pdf/skyrizi_pi.pdf | SKYRIZI™ (risankizumab-rzaa) Full Prescribing Information |
/pdf/skyrizi_pi_SPA.pdf | SKYRIZI™ (risankizumab-rzaa) Full Prescribing Information - Spanish |
/pdf/skyrizi_medguide.pdf | SKYRIZI™ (risankizumab-rzaa) Medication Guide |
/pdf/survanta_pi.pdf | SURVANTA® (beractant) intratracheal suspension Full Prescribing Information |
/pdf/synthroid.pdf | SYNTHROID® (levothyroxine sodium tablets, USP) |
/htm/synthroid/synthroid_pi.html | SYNTHROID® (levothyroxine sodium tablets, USP) |
/pdf/synthroid_SPA.pdf | SYNTHROID® (levothyroxine sodium tablets, USP) - Spanish |
/pdf/tarka.pdf | TARKA® (trandolapril/verapamil HCI ER) |
/pdf/technivie_pi.pdf | TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Full Prescribing Information and Medication Guide |
/htm/technivie/technivie_pi.html | TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Full Prescribing Information and Medication Guide |
/pdf/technivie_medguide.pdf | TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Medication Guide |
/pdf/tricorpi.pdf | TRICOR® (fenofibrate) tablets |
/pdf/tridione_pi.pdf | TRIDIONE® (trimethadione) Tablets |
/pdf/trilipix_pi.pdf | TRILIPIX® (fenofibric acid) delayed-release capsules - Full Prescribing Information |
/pdf/ultanepi.pdf | ULTANE® (sevoflurane) |
/pdf/ultanenovaplus_pi.pdf | ULTANE® (sevoflurane) - NOVAPLUS® |
/pdf/venclexta.pdf | VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information |
/htm/venclexta/venclexta_pi.html | VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information |
/pdf/venclexta_SPA.pdf | VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information - Spanish |
/pdf/venclexta_medguide.pdf | VENCLEXTA® (venetoclax tablets) for oral use Medication Guide |
/pdf/vicodin_apap_300mg_hydrocodone_5mg-7_5mg-10mg_PI.pdf | VICODIN® (hydrocodone bitartrate and acetaminophen tablets, USP) 5 mg/300 mg; VICODIN ES® (hydrocodone bitartrate and acetaminop... |
/pdf/viekirapak_pi.pdf | VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Full Prescribing Inf... |
/viekirapak/viekirapak_pi.html | VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Full Prescribing Inf... |
/pdf/viekirapak_medguide.pdf | VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Medication Guide |
/pdf/viekiraxr_medguide.pdf | VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Medication Guide |
/pdf/viekiraxr_pi.pdf | VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Full Prescribing Informa... |
/htm/viekiraxr/viekiraxr_pi.html | VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Full Prescribing Informa... |
/pdf/Zemplarcappi.pdf | ZEMPLAR® (paricalcitol) Capsules |
/pdf/zemplarivpi.pdf | ZEMPLAR® (paricalcitol) Injection |
/htm/zemplariv/zemplariv_pi.html | ZEMPLAR® (paricalcitol) Injection |
[Querying whois.verisign-grs.com]
[Redirected to whois.markmonitor.com]
[Querying whois.markmonitor.com]
[whois.markmonitor.com]
MarkMonitor is the Global Leader in Online Brand Protection.
MarkMonitor Domain Management(TM)
MarkMonitor Brand Protection(TM)
MarkMonitor AntiPiracy(TM)
MarkMonitor AntiFraud(TM)
Professional and Managed Services
Visit MarkMonitor at www.markmonitor.com
Contact us at 1 (800) 745-9229
In Europe, at +44 (0) 203 206 2220
The Data in MarkMonitor.com's WHOIS database is provided by MarkMonitor.com
for information purposes, and to assist persons in obtaining information
about or related to a domain name registration record. MarkMonitor.com
does not guarantee its accuracy. By submitting a WHOIS query, you agree
that you will use this Data only for lawful purposes and that, under no
circumstances will you use this Data to: (1) allow, enable, or otherwise
support the transmission of mass unsolicited, commercial advertising or
solicitations via e-mail (spam); or (2) enable high volume, automated,
electronic processes that apply to MarkMonitor.com (or its systems).
MarkMonitor.com reserves the right to modify these terms at any time.
By submitting this query, you agree to abide by this policy.
Registrant:
Domain Name Administrator
Abbott Laboratories
100 Abbott Park Road
Abbott Park IL 60064
US
abtlabinternetnsa@abbott.com +1.8479376100 Fax: +1.8479385558
Domain Name: rxabbott.com
Registrar Name: Markmonitor.com
Registrar Whois: whois.markmonitor.com
Registrar Homepage: http://www.markmonitor.com
Administrative Contact:
Domain Name Administrator
Abbott Laboratories
100 Abbott Park Road
Abbott Park IL 60064
US
abtlabinternetnsa@abbott.com +1.8479376100 Fax: +1.8479385558
Technical Contact, Zone Contact:
Domain Name Administrator
Abbott Laboratories
100 Abbott Park Road
Abbott Park IL 60064
US
abtlabinternetnsa@abbott.com +1.8479376100 Fax: +1.8479385558
Created on..............: 1996-12-06.
Expires on..............: 2013-12-04.
Record last updated on..: 2013-02-22.
Domain servers in listed order:
rossns2.abbott.com
abtnsdmz1.abbott.com
abtnsdmz2.abbott.com
rossns.abbott.com
MarkMonitor is the Global Leader in Online Brand Protection.
MarkMonitor Domain Management(TM)
MarkMonitor Brand Protection(TM)
MarkMonitor AntiPiracy(TM)
MarkMonitor AntiFraud(TM)
Professional and Managed Services
Visit MarkMonitor at www.markmonitor.com
Contact us at 1 (800) 745-9229
In Europe, at +44 (0) 203 206 2220
США - Deerfield - 130.36.45.5
Abbott Laboratories
Abbott Laboratories
HTTP/1.1 200 OK
Date: Tue, 21 Jan 2020 00:37:22 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 35198
Connection: keep-alive
Set-Cookie: AWSALB=ObuVwcPE4uIgPS7ObwLl+CwsZDKRTTokn1masYT7s5+9K8SdMSXPwfV5wiAT5hY/car3PuNoL+13L9oks/9sZN6jCwDUXZ9yUUeZS14MjZupszxnoCSNySoEKHGo; Expires=Tue, 28 Jan 2020 00:37:22 GMT; Path=/
Server: Apache
Age: 2763
Last-Modified: Mon, 20 Jan 2020 23:51:19 GMT
ETag: "897e-59c9af7cc7fc4"
Accept-Ranges: bytes
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"